logo-loader
RNS
Corilis Digital Infrastructure Limited

Notice of 2026 Interim Results

RNS Number : 9087D
Corilis Digital Infrastructure Ltd
19 November 2026
 

19 November 2026

 

CORILIS DIGITAL INFRASTRUCTURE LIMITED

 

NOTICE OF 2026 INTERIM RESULTS

 

Corilis Digital Infrastructure Limited formerly Cordiant Digital Infrastructure Limited (the Company or CORD), the FTSE 250 specialist investor in and operator of digital infrastructure, announces that it will be publishing its interim results for the six-month period ended 30 September 2026 on 24 November 2026.

 

A meeting for analysts will be held on the day of the results in person at 10:00am GMT at the offices of Investec, 30 Gresham Street, London, EC2V 7QN. For those wishing to attend, please contact Celicourt via CDI@celicourt.uk.

For further information, please visit https://www.corilisdigitaltrust.com/ or contact:

 

Cordiant Capital Inc (Investment Manager)

 

Corilis Digital Infrastructure Management LLP

Stephen Foss

CordiantDigitalTrust@cordiantcap.com

Aztec Financial Services (Guernsey) Limited

(Company secretary and administrator)

+44 (0)1481 749 700

cord@aztecgroup.co.uk

Investec Bank plc (Joint corporate broker)

Lucy Lewis

Tom Skinner

+44 (0)20 7597 4000

 

 

Deutsche Numis (Joint corporate broker)

Hugh Jonathan

George Shiel

+44 (0)20 7260 1000

 

Celicourt (Financial communications adviser)

Philip Dennis

Kathleen Beams

+44 (0)20 7770 6424

 CDI@celicourt.uk

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORUKUURNRUAAAA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Allergy Therapeutics, Helium One Global, Rockfire Resources, Cordiant...

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) grew second-half sales by more than 12% after launching its grass pollen treatment Grassmuno in Germany, its largest market. Annual revenue rose 9% to £59.9 million, but the operating loss widened to £38.6 million, and shareholders will vote on...

6 days, 11 hours ago

2 min read